Electrostatic Mopping of Viruses with Medicinal Synthetic Aluminum-Magnesium Silicate {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3}, for Quick Cure of COVID-19: A Better Control Measure

Ezeibe, Maduike C. O. and Onyeachonam, Favour and Sanda, Mary E. and Ogbonna, Ijeoma J. and Kalu, Ekenma and Njoku, Njoku U. and Udobi, Munachi (2021) Electrostatic Mopping of Viruses with Medicinal Synthetic Aluminum-Magnesium Silicate {Al4(SiO4)3 + 3Mg2SiO4 → 2Al2Mg3(SiO4)3}, for Quick Cure of COVID-19: A Better Control Measure. Open Journal of Epidemiology, 11 (03). pp. 278-283. ISSN 2165-7459

[thumbnail of ojepi_2021080214333193.pdf] Text
ojepi_2021080214333193.pdf - Published Version

Download (241kB)

Abstract

COVID-19 virus has positive electrical charges. So, particles that are negatively charged would, by opposite charges-electrostatic attraction, inhibit its replication’s first stage (attachment to cells) and mop its extra-cellular particles. Positively charged particles would similarly mop/destroy cells it infects because unlike healthy cells which are neutral, infected/tumor cells have negative electrical charges. Nanoparticles (0.96 nm) of Aluminum-magnesium silicate (AMS), WHO-approved medicine/adjuvant have both negative and positive charged ends. As adjuvant it improves antimicrobials’ efficacies (clearing secondary infections) while as silicate it enhances immunity. By inhibiting viral replication; mopping extra-cellular viruses/abnormal cells; clearing secondary infections; enhancing immunity, AMS terminates viral-infections/abnormal cells’ metastases. Natural AMS has impurities and its deposits are not found in Nigeria. So, Aluminum silicate and Magnesium silicate (WHO-approved medicines) were used for Medicinal synthetic AMS {MSAMS: Al4 (SiO4)3 + 3Mg2SiO4 → 2Al2Mg3 (SiO4)3}. Since AMS is un-absorbable, dextrose monohydrate is incorporated in MSAMS-formulations to convey its Nanoparticles into blood for circulation to all organs/tissues (active-transportation). The MSAMS achieved quick cure (within 3 days) of all four COVID-19 patients used for its first-phase trial (one in Nigeria, two in Cameroon, one in Tanzania).

Item Type: Article
Subjects: Lib Research Guardians > Medical Science
Depositing User: Unnamed user with email support@lib.researchguardians.com
Date Deposited: 31 May 2023 07:23
Last Modified: 17 Jan 2024 04:33
URI: http://journal.edit4journal.com/id/eprint/1178

Actions (login required)

View Item
View Item